

Information Request Email, May 20, 2014 - GARDASIL 9

RECORD OF EMAIL COMMUNICATION

Submission Type: BLA Submission ID: 125508/0 Office: OVRR

Product: Human Papillomavirus 9-valent Vaccine, Recombinant

Applicant: Merck Sharp & Dohme Corp.

Telecon Date/Time: 20-May-2014 05:54 PM

Initiated by FDA? Yes

Telephone Number: N/A (email)

Communication Category: Information Request

Author: Laura Montague

Telecon Summary: IR #10 - requested (1) information regarding clinical site V503-001-(b)(4)(b)(6) and (2) clarification regarding LRPs

FDA Participants: Laura Montague

Non-FDA Participants: Alison Fisher

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Telecon Body:

From: Montague, Laura

Sent: Tuesday, May 20, 2014 5:54 PM

To: alison_fisher@merck.com

Cc: Khurana, Bharat

Subject: STN 125508/0; Information Request #10

Dear Alison,

We have the following information requests regarding your supplement 125508.

1. It has come to CBER's attention that issues were identified regarding non-compliance with Good Clinical Practice for an investigational product (not 9vHPV) being studied at the clinical site of -----(b)(4)(b)(6)--- (V503-001-(b)(4)(b)(6)). In review of study V503-001, we note that 495 subjects/14215 subjects in V503-001 were vaccinated with the mid-dose 9vHPV vaccine or qHPV at this site (3.48% of subjects).
 - (a) Please indicate whether Merck has conducted an internal audit of site V503-001-(b)(4)(b)(6) for protocol V503-001 or whether an internal audit is planned.
 - (b) If an internal audit has not been conducted, please provide an assessment of feasibility of conducting such an audit within the time frame of the review of STN 125508.
2. Please clarify how you intend to submit the lot release protocols for bulks of the original 4 HPV types in Gardasil. Will you be submitting to 125126 or 122508, or both?

Thank you,

Laura Montague

Regulatory Project Manager

FDA/CBER/OVRR

Division of Vaccines and Related Product Applications

phone: (301)796-2640

fax: (301)595-1244

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.